CN111728214A - 一种辅助逆转糖尿病的药食用组合物 - Google Patents
一种辅助逆转糖尿病的药食用组合物 Download PDFInfo
- Publication number
- CN111728214A CN111728214A CN202010810400.4A CN202010810400A CN111728214A CN 111728214 A CN111728214 A CN 111728214A CN 202010810400 A CN202010810400 A CN 202010810400A CN 111728214 A CN111728214 A CN 111728214A
- Authority
- CN
- China
- Prior art keywords
- extract
- diabetes
- assisting
- reversing
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 41
- 239000000203 mixture Substances 0.000 title claims abstract description 22
- 239000000284 extract Substances 0.000 claims abstract description 41
- 239000003814 drug Substances 0.000 claims abstract description 31
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 26
- 239000000843 powder Substances 0.000 claims abstract description 16
- 206010022489 Insulin Resistance Diseases 0.000 claims abstract description 14
- 240000000249 Morus alba Species 0.000 claims abstract description 14
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 14
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims abstract description 14
- 241001264174 Cordyceps militaris Species 0.000 claims abstract description 12
- 235000013305 food Nutrition 0.000 claims abstract description 12
- 240000000950 Hippophae rhamnoides Species 0.000 claims abstract description 10
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims abstract description 10
- 241000251511 Holothuroidea Species 0.000 claims abstract description 10
- 240000004371 Panax ginseng Species 0.000 claims abstract description 9
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 9
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 9
- 235000008434 ginseng Nutrition 0.000 claims abstract description 9
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 9
- 239000011707 mineral Substances 0.000 claims abstract description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 9
- 229940088594 vitamin Drugs 0.000 claims abstract description 8
- 239000011782 vitamin Substances 0.000 claims abstract description 8
- 235000002722 Dioscorea batatas Nutrition 0.000 claims abstract description 7
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims abstract description 7
- 240000001811 Dioscorea oppositifolia Species 0.000 claims abstract description 7
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims abstract description 7
- 244000130270 Fagopyrum tataricum Species 0.000 claims abstract description 7
- 235000014693 Fagopyrum tataricum Nutrition 0.000 claims abstract description 7
- 235000009811 Momordica charantia Nutrition 0.000 claims abstract description 7
- 229920001100 Polydextrose Polymers 0.000 claims abstract description 7
- 244000197580 Poria cocos Species 0.000 claims abstract description 7
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 7
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims abstract description 7
- 229940107187 fructooligosaccharide Drugs 0.000 claims abstract description 7
- 235000013336 milk Nutrition 0.000 claims abstract description 7
- 239000008267 milk Substances 0.000 claims abstract description 7
- 210000004080 milk Anatomy 0.000 claims abstract description 7
- 239000001259 polydextrose Substances 0.000 claims abstract description 7
- 235000013856 polydextrose Nutrition 0.000 claims abstract description 7
- 229940035035 polydextrose Drugs 0.000 claims abstract description 7
- 229920001202 Inulin Polymers 0.000 claims abstract description 6
- 229920002752 Konjac Polymers 0.000 claims abstract description 6
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 claims abstract description 6
- 240000002624 Mespilus germanica Species 0.000 claims abstract description 6
- 235000017784 Mespilus germanica Nutrition 0.000 claims abstract description 6
- 235000000560 Mimusops elengi Nutrition 0.000 claims abstract description 6
- 244000185386 Thladiantha grosvenorii Species 0.000 claims abstract description 6
- 235000011171 Thladiantha grosvenorii Nutrition 0.000 claims abstract description 6
- 235000007837 Vangueria infausta Nutrition 0.000 claims abstract description 6
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 6
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 6
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims abstract description 6
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 6
- 229940029339 inulin Drugs 0.000 claims abstract description 6
- 235000010485 konjac Nutrition 0.000 claims abstract description 6
- 235000021119 whey protein Nutrition 0.000 claims abstract description 6
- 239000004376 Sucralose Substances 0.000 claims abstract description 5
- 235000010755 mineral Nutrition 0.000 claims abstract description 5
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims abstract description 5
- 235000019408 sucralose Nutrition 0.000 claims abstract description 5
- 229930003231 vitamin Natural products 0.000 claims abstract description 4
- 235000013343 vitamin Nutrition 0.000 claims abstract description 4
- 241000756042 Polygonatum Species 0.000 claims abstract 2
- 235000013339 cereals Nutrition 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- 244000302512 Momordica charantia Species 0.000 claims description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 6
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 5
- 230000036541 health Effects 0.000 claims description 5
- 235000013312 flour Nutrition 0.000 claims description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 3
- 244000247812 Amorphophallus rivieri Species 0.000 claims description 3
- 235000001206 Amorphophallus rivieri Nutrition 0.000 claims description 3
- 244000077995 Coix lacryma jobi Species 0.000 claims description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 3
- 108010038807 Oligopeptides Proteins 0.000 claims description 3
- 102000015636 Oligopeptides Human genes 0.000 claims description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 3
- 244000062793 Sorghum vulgare Species 0.000 claims description 3
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 3
- 229930003451 Vitamin B1 Natural products 0.000 claims description 3
- 229930003471 Vitamin B2 Natural products 0.000 claims description 3
- 229930003268 Vitamin C Natural products 0.000 claims description 3
- 229930003427 Vitamin E Natural products 0.000 claims description 3
- 240000008042 Zea mays Species 0.000 claims description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 3
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims description 3
- 239000001354 calcium citrate Substances 0.000 claims description 3
- 229960004256 calcium citrate Drugs 0.000 claims description 3
- 235000005822 corn Nutrition 0.000 claims description 3
- 229960000304 folic acid Drugs 0.000 claims description 3
- 235000019152 folic acid Nutrition 0.000 claims description 3
- 239000011724 folic acid Substances 0.000 claims description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 3
- 239000000252 konjac Substances 0.000 claims description 3
- 235000019713 millet Nutrition 0.000 claims description 3
- 235000001968 nicotinic acid Nutrition 0.000 claims description 3
- 229960003512 nicotinic acid Drugs 0.000 claims description 3
- 239000011664 nicotinic acid Substances 0.000 claims description 3
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 3
- 229960002477 riboflavin Drugs 0.000 claims description 3
- 229960003495 thiamine Drugs 0.000 claims description 3
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 3
- 235000013337 tricalcium citrate Nutrition 0.000 claims description 3
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 claims description 3
- 235000019155 vitamin A Nutrition 0.000 claims description 3
- 239000011719 vitamin A Substances 0.000 claims description 3
- 235000010374 vitamin B1 Nutrition 0.000 claims description 3
- 239000011691 vitamin B1 Substances 0.000 claims description 3
- 235000019164 vitamin B2 Nutrition 0.000 claims description 3
- 239000011716 vitamin B2 Substances 0.000 claims description 3
- 235000019158 vitamin B6 Nutrition 0.000 claims description 3
- 239000011726 vitamin B6 Substances 0.000 claims description 3
- 235000019154 vitamin C Nutrition 0.000 claims description 3
- 239000011718 vitamin C Substances 0.000 claims description 3
- 235000019165 vitamin E Nutrition 0.000 claims description 3
- 239000011709 vitamin E Substances 0.000 claims description 3
- 229940046009 vitamin E Drugs 0.000 claims description 3
- 229940045997 vitamin a Drugs 0.000 claims description 3
- 229940011671 vitamin b6 Drugs 0.000 claims description 3
- 229940068475 zinc citrate Drugs 0.000 claims description 3
- 235000006076 zinc citrate Nutrition 0.000 claims description 3
- 239000011746 zinc citrate Substances 0.000 claims description 3
- 240000001548 Camellia japonica Species 0.000 claims 1
- 244000241838 Lycium barbarum Species 0.000 claims 1
- 235000015459 Lycium barbarum Nutrition 0.000 claims 1
- 235000015468 Lycium chinense Nutrition 0.000 claims 1
- 241001122767 Theaceae Species 0.000 claims 1
- 235000008322 Trichosanthes cucumerina Nutrition 0.000 claims 1
- 235000018597 common camellia Nutrition 0.000 claims 1
- 244000269722 Thea sinensis Species 0.000 abstract description 11
- 230000007246 mechanism Effects 0.000 abstract description 7
- 230000036039 immunity Effects 0.000 abstract description 6
- 230000002441 reversible effect Effects 0.000 abstract description 6
- 235000013325 dietary fiber Nutrition 0.000 abstract description 5
- 210000000653 nervous system Anatomy 0.000 abstract description 5
- 235000018102 proteins Nutrition 0.000 abstract description 5
- 102000004169 proteins and genes Human genes 0.000 abstract description 5
- 108090000623 proteins and genes Proteins 0.000 abstract description 5
- 230000004060 metabolic process Effects 0.000 abstract description 4
- 210000002569 neuron Anatomy 0.000 abstract description 4
- 235000009812 Momordica cochinchinensis Nutrition 0.000 abstract description 3
- 235000018365 Momordica dioica Nutrition 0.000 abstract description 3
- 244000046146 Pueraria lobata Species 0.000 abstract description 3
- 235000010575 Pueraria lobata Nutrition 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 2
- 230000006641 stabilisation Effects 0.000 abstract description 2
- 238000011105 stabilization Methods 0.000 abstract description 2
- 240000001910 Momordica cochinchinensis Species 0.000 abstract 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 47
- 210000004369 blood Anatomy 0.000 description 29
- 239000008280 blood Substances 0.000 description 29
- 102000004877 Insulin Human genes 0.000 description 24
- 108090001061 Insulin Proteins 0.000 description 24
- 229940125396 insulin Drugs 0.000 description 23
- 108010075254 C-Peptide Proteins 0.000 description 15
- 230000000694 effects Effects 0.000 description 13
- 229940079593 drug Drugs 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 230000003647 oxidation Effects 0.000 description 7
- 238000007254 oxidation reaction Methods 0.000 description 7
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 6
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000006187 pill Substances 0.000 description 6
- 230000001603 reducing effect Effects 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 108091005995 glycated hemoglobin Proteins 0.000 description 4
- 230000002218 hypoglycaemic effect Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 208000013016 Hypoglycemia Diseases 0.000 description 3
- 229940100389 Sulfonylurea Drugs 0.000 description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide dismutase Proteins 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000003750 conditioning effect Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 229930189775 mogroside Natural products 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 2
- 108010076181 Proinsulin Proteins 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000016097 disease of metabolism Diseases 0.000 description 2
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 2
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 229960004329 metformin hydrochloride Drugs 0.000 description 2
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 238000007410 oral glucose tolerance test Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- LLJFMFZYVVLQKT-UHFFFAOYSA-N 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-2-isoquinolinyl)ethyl]phenyl]sulfonylurea Chemical compound C=1C(OC)=CC=C(C(C2=O)(C)C)C=1C(=O)N2CCC(C=C1)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 LLJFMFZYVVLQKT-UHFFFAOYSA-N 0.000 description 1
- 206010002065 Anaemia megaloblastic Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229940122199 Insulin secretagogue Drugs 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 102000016261 Long-Acting Insulin Human genes 0.000 description 1
- 108010092217 Long-Acting Insulin Proteins 0.000 description 1
- 229940100066 Long-acting insulin Drugs 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000000682 Megaloblastic Anemia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 235000001188 Peltandra virginica Nutrition 0.000 description 1
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 description 1
- GHUUBYQTCDQWRA-UHFFFAOYSA-N Pioglitazone hydrochloride Chemical compound Cl.N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 GHUUBYQTCDQWRA-UHFFFAOYSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 108010026951 Short-Acting Insulin Proteins 0.000 description 1
- 229940123958 Short-acting insulin Drugs 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000006538 anaerobic glycolysis Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 description 1
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000021196 dietary intervention Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000000225 effect on diabetes Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 229960000346 gliclazide Drugs 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 229960003468 gliquidone Drugs 0.000 description 1
- 208000018914 glucose metabolism disease Diseases 0.000 description 1
- 238000007446 glucose tolerance test Methods 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100001016 megaloblastic anemia Toxicity 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229960000698 nateglinide Drugs 0.000 description 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- BNYHRGTXRPWASY-UHFFFAOYSA-N nonylsulfonylurea Chemical compound CCCCCCCCCS(=O)(=O)NC(N)=O BNYHRGTXRPWASY-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229960002827 pioglitazone hydrochloride Drugs 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229960002354 repaglinide Drugs 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- SUFUKZSWUHZXAV-BTJKTKAUSA-N rosiglitazone maleate Chemical compound [H+].[H+].[O-]C(=O)\C=C/C([O-])=O.C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O SUFUKZSWUHZXAV-BTJKTKAUSA-N 0.000 description 1
- 229960003271 rosiglitazone maleate Drugs 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/25—Synthetic polymers, e.g. vinylic or acrylic polymers
- A23L33/26—Polyol polyesters, e.g. sucrose polyesters; Synthetic sugar polymers, e.g. polydextrose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/616—Echinodermata, e.g. starfish, sea cucumbers or sea urchins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明为一种辅助逆转糖尿病的药食用组合物,包括有聚葡萄糖、混合谷物粉、海参、乳粉、乳清蛋白、低聚果糖、苦荞提取物、人参、黄精提取物、山药、桑葚、枸杞提取物、茯苓、桑叶提取物、葛根、苦瓜肽、魔芋、沙棘提取物、茶树花提取物、L‑阿拉伯糖、蛹虫草、罗汉果、菊粉、三氯蔗糖以及多矿多维。本发明通过提供膳食纤维、蛋白、矿物质和维生素,并结合药食同源的机理,充分利用各药材原理成分,实现稳糖、控糖,改善糖耐量,减轻胰岛素抵抗,增强免疫力,恢复身体机能,调节代谢,滋养神经细胞,恢复神经系统功能,有效缓解防治糖尿病多种并发症,大大改善生活质量,能有效防治糖尿病,尤其是对2型糖尿病可有效改善和逆转。
Description
【技术领域】
本发明涉及一种辅助逆转糖尿病的药食用组合物。
【背景技术】
据WHO(World Health Organization)发布的信息称,全球死亡率最高的四大慢性疾病分别为癌症(cancer)、心脏病(cardiovascular disease)、肺病(chronicrespiratory disease)和糖尿病(diabetes)。而糖尿病在人们的日常生活当中较为常见,且越来越年轻化。
糖尿病是一种以高血糖为特征的代谢性疾病。这种疾病会给患者的生活和健康带来极大的影响,且治疗时长较长,大多数患者均需要终身服药,少数患者也会出现一些并发症。
目前,治疗糖尿病的医用药,均能有效降低血糖,但是有不同的药物副作用。如:
1、胰岛素
包括短效胰岛素、中长效胰岛素注射剂、胰岛素类似物、预混胰岛素等。该类制剂主要适用于需要采用胰岛素来维持正常血糖水平患者的治疗,常见不良反应是低血糖及体重增加;
2、格列奈类药物
常用的药物有瑞格列奈和那格列奈,为非磺脲类促胰岛素分泌剂,主要通过刺激胰岛素的早期分泌相降低餐后血糖,其特点为吸收快、起效快、作用时间短。常见不良反应也是低血糖,但发生率和严重程度磺脲类药物轻;
3、双胍类药物
此类药物包括盐酸二甲双胍、盐酸二甲双胍缓释片;其作用机理为不促进胰岛素分泌,其降糖作用机理是促进组织无氧糖酵解,加强肌肉等组织对葡萄糖的利用,同时抑制肝糖原的异生,减少葡萄糖的产生;但是易产生胃肠道反应,令VB12缺乏,导致巨幼细胞贫血;
4、噻唑烷二酮类药物
此类药物包括盐酸曲格列酮、马来酸罗格列酮、盐酸吡格列酮等,是一种具有高选择性PPARγ激动剂。其作用机理为通过增加胰岛素的敏感性而有效地控制血糖;但是,常见不良反应是增加皮下脂肪,可能导致或加重充血性心功能衰竭;
5、磺酰脲类药物
此类药物包括格列苯脲、格列吡嗪、格列喹酮、格列齐特、格列美脲等,其作用机理为刺激胰岛β细胞分泌胰岛素,从而降低血糖。磺酰脲类药物是非肥胖的2型糖尿病病人的一线治疗药物,所有的磺酰脲类药物均能引起低血糖。
目前在全世界范围内,从长远角度来说,尚未发现能够治愈糖尿病的方法和药物(治愈:是指医生在经过各种治疗后,将患者的疾病原因彻底清除,让患者回到患病前的状态),因此,我们希望能够开发一种药食用组合物,对糖尿病进行控制,直至逆转(通过治疗或干预,使患者的疾病有所好转,保持着相对健康的状态)。
针对上述问题,申请人提出了一种解决方案。
【发明内容】
本发明的目的是在于克服现有技术的不足,提供了一种辅助逆转糖尿病的药食用组合物。
为了解决上述存在的技术问题,本发明采用下述技术方案:
一种辅助逆转糖尿病的药食用组合物,包括有聚葡萄糖、混合谷物粉、海参、乳粉、乳清蛋白、低聚果糖、苦荞提取物、人参、黄精提取物、山药、桑葚、枸杞提取物、茯苓、桑叶提取物、葛根、苦瓜肽、魔芋、沙棘提取物、茶树花提取物、L-阿拉伯糖、蛹虫草、罗汉果、菊粉、三氯蔗糖以及多矿多维。
上述原料按质量百分比计,优先的,包括有聚葡萄糖15%、混合谷物粉16%、海参1%、乳粉28%、乳清蛋白1%、低聚果糖1%、苦荞提取物6%、人参1%、黄精提取物3%、山药2%、桑葚1%、枸杞提取物2%、茯苓2%、桑叶提取物2%、葛根2%、苦瓜肽4%、魔芋4%、沙棘提取物2%、茶树花提取物2%、L-阿拉伯糖1%、蛹虫草1%、罗汉果1%、菊粉1%、三氯蔗糖0.5%以及多矿多维0.5%。
优选的,所述混合谷物粉包括有薏米、玉米低聚肽粉和小米。
优选的,所述多矿多维包括有维生素C、维生素A、维生素E、维生素B1、维生素B2、维生素B6、烟酸、叶酸、柠檬酸钙和柠檬酸锌。
本发明所得的一种辅助逆转糖尿病的药食用组合物可以作为临床治疗II型糖尿病和逆转胰岛素抵抗的药物中的应用。
本发明所得的一种辅助逆转糖尿病的药食用组合物可以作为临床治疗II型糖尿病和逆转胰岛素抵抗的保健品中的应用。
与现有技术相比,本发明的有益效果是:本发明通过提供膳食纤维、蛋白、矿物质和维生素,并结合药食同源的机理,充分利用各药材原理成分,实现稳糖、控糖,改善糖耐量,减轻胰岛素抵抗,增强免疫力,恢复身体机能,调节代谢,滋养神经细胞,恢复神经系统功能,有效改善周围神经病变的症状,有效缓解防治糖尿病多种并发症,大大改善生活质量,能有效防治糖尿病,尤其是对2型糖尿病可有效改善和逆转。
下面结合具体实施方式对本发明作进一步的详细描述:
【具体实施方式】
一种辅助逆转糖尿病的药食用组合物,按质量百分比计,包括有聚葡萄糖15%、混合谷物粉16%、海参1%、乳粉28%、乳清蛋白1%、低聚果糖1%、苦荞提取物6%、人参1%、黄精提取物3%、山药2%、桑葚1%、枸杞提取物2%、茯苓2%、桑叶提取物2%、葛根2%、苦瓜肽4%、魔芋4%、沙棘提取物2%、茶树花提取物2%、L-阿拉伯糖1%、蛹虫草1%、罗汉果1%、菊粉1%、三氯蔗糖0.5%以及多矿多维0.5%;所述混合谷物粉包括有薏米、玉米低聚肽粉和小米;所述多矿多维包括有维生素C、维生素A、维生素E、维生素B1、维生素B2、维生素B6、烟酸、叶酸、柠檬酸钙和柠檬酸锌。
本发明所得的一种辅助逆转糖尿病的药食用组合物可以作为临床治疗II型糖尿病和逆转胰岛素抵抗的药物中的应用。
本发明所得的一种辅助逆转糖尿病的药食用组合物可以作为临床治疗II型糖尿病和逆转胰岛素抵抗的保健品中的应用。
在本发明中,原料的功能如下:
人参:人参皂苷Rg1作为人参中的主要活性成分,具有抗炎症、抗氧化、抗凋亡、脂质调节和降低血糖等作用,人参皂苷Rg1对糖尿病导致的并发症心肌病、肾病、脂肪肝等具有一定的缓解作用;
海参:现代药理研究表明,海参具有多种药理活性,包括抗氧化、延缓衰老、抗凝血、抗血栓、降血脂、降低血粘度、抗肿瘤、免疫调节、抗菌、抗病毒及促细胞生长等作用,能显著降低动物空腹血糖值、胰岛素抵抗指数以及肝组织中PTP-1BmRNA表达水平,增加血清中胰岛素含量、胰岛素敏感性及肝组织中IRS-2mRNA表达水平,对2型糖尿病发挥改善作用;其次,海参肽能不同程度地改善2型糖尿病的体征状况,减轻多饮、多食、多尿的“三多”症状,提高2型糖尿病的生活质量;
蛹虫草:蛹虫草的SOD活力和抗氧化能力很强,且耐高温,性质稳定;虫草素及腺苷是蛹虫草中的两种主要活性成分,具有调节免疫、抗氧化及抗衰老等重要生理功效,具有潜在的对糖尿病肾脏氧化应激的治疗效果;蛹虫草多糖显示出较好的降血糖效果,能明显降低糖尿病血糖值,且在一定范围内能改善糖耐量异常,同时能有效减轻高血糖对肾脏和肝脏的损伤和缓解由糖代谢紊乱所引发的体重下降问题;
罗汉果:罗汉果苷基本无毒,且具有抗氧化、调节血糖等多种生物活性;罗汉果甜苷具有一定的肥胖抑制作用,在不影响饮食量的前提下具有一定的抑制体重增涨、降低附睾脂肪组织和肾周脂肪组织重量的作用;罗汉果甜苷有改善系统性糖耐量和胰岛素敏感性的作用,与阿斯巴甜相反,罗汉果甜苷对糖尿病有一定预防作用;
沙棘:沙棘具有多成分、多靶点、多途径调节糖尿病的作用特点,沙棘黄酮的药理作用包括抗血栓形成、降血脂、抗动脉粥样硬化、降血压、降血糖、增强免疫功能、抗肿瘤、抗菌、抗辐射等;
茶树花:茶树花含有茶多糖、蛋白质、氨基酸、茶多酚、茶皂甙、超氧化物歧化酶(SOD)和过氧化氢酶(CAT)等多种有益成分和活性物质,这些成分对人体具有解毒、抑菌、降糖、防癌抗癌、抗氧化和增强免疫力等功效,茶树花多糖对糖尿病有明显的防治作用。
本发明提供了可溶性膳食纤维(聚葡萄糖和混合谷物粉),以达到促进消化,预防便秘、调节血脂、血糖的作用;膳食纤维的存在,它能够延缓我们的食物在肠道中的吸收,膳食纤维有助于降低胆固醇,对血脂的控制也有一定的作用;在患者的糖耐量实验、糖化血红蛋白检查、C肽释放实验、胰岛素抵抗和胰岛β细胞功能检查结果显示,与膳食干预之前相比,膳食纤维干预之后,患者血液中血糖和糖化血红蛋白均减少,糖耐量得到改善,并且C肽释放减少,胰岛素抵抗减轻。
本发明提供了优质蛋白(海参、乳粉、乳清蛋白和低聚果糖),人体必需氨基酸高,利用率高,营养价值高,有利于保护肾脏,利于糖尿病肾病的防治。
本发明利用了药食同源的机理,提供了苦荞提取物、人参、黄精提取物、山药、桑葚、枸杞提取物、茯苓、桑叶提取物、葛根、苦瓜肽、沙棘提取物、茶树花提取物、蛹虫草、罗汉果,以调理身体机能,恢复代谢,激活修复受损胰岛β细胞,解除胰岛素抵抗,提高胰岛降糖效率,调节血糖平衡,调理气血,全面防治糖尿病及并发症的发生;
本发明还提供了丰富的矿物质和维生素,能够有力的清除自由基,抗氧化,清除神经细胞内的代谢垃圾,消除神经系统微循环障碍,加速营养供给,恢复神经系统正常代谢功能,同时微量元素还可滋养神经细胞,恢复神经系统功能,从而有效改善糖尿病周围神经病变的症状,2型糖尿病作为慢性代谢性疾病,易发生各种微血管和大血管并发症。矿物质作为微量营养素,机体需求量虽少,但对机体的新陈代谢至关重要,在糖尿病及并发症的发生中起着重要作用。
应用案例1:陈先生,76岁,2013年,广东省中医院珠海医院确诊为二型糖尿病。平时每天注射20个单位胰岛素。2018年8月10日开始接受调理,服用本辅助逆转糖尿病的药食用组合物按常规工艺制备而成的丸剂,2018年8月09日在广东省中医院珠海医院通过亲和高效液相色谱法测得其糖化血红蛋白Alc(HbAlc)的结果为10.00%(参考值区间为4.00-6.50%),在调理4个月后(在调理期间,正常科学饮食),2018年12月04日在广东省中医院珠海医院通过亲和高效液相色谱法测得其糖化血红蛋白Alc(HbAlc)的结果为6.40%(参考值区间为4.00-6.50%)。
应用案例2:欧阳女士,85岁,2016年,广东省中医院珠海医院确诊为二型糖尿病不伴有并发症。2019年7月6日开始接受调理,服用本辅助逆转糖尿病的药食用组合物按常规工艺制备而成的丸剂,2019年10月05日在广东省中医院珠海医院通过化学发光检验,检验数据如下表:
标本 | 项目 | 结果 | 单位 | 参考区间 |
静脉血 | C肽(CPS) | 2.47 | ng/ml | 0.4-3.6 |
餐后1h血清 | C肽(CPS) | 3.05 | ng/ml | |
餐后2h血清 | C肽(CPS) | 3.92 | ng/ml |
我们知道糖化血红蛋白是衡量血糖控制的金标准,也是诊断和管理糖尿病的重要手段。在糖尿病治疗中,糖化血红蛋白水平对评价血糖总体控制、发现治疗中存在的问题以及指导治疗方案均有重要的临床意义。通过应用案例1,我们可以发现,在服用本辅助逆转糖尿病的药食用组合物按常规工艺制备而成的丸剂后,可以有效控糖、稳糖、降糖。
另外,正常情况下,人胰岛细胞主要分泌产生并释放到血液中的是胰岛素,在产生胰岛素的一系列过程中,胰岛细胞首先合成胰岛素原,胰岛素原是一条很长的蛋白质链,胰岛素原在转化酶作用下被分解为三段,前后两段又重新联接成为A链和B链组成的胰岛素,中间一段独立出来的就是C肽。因此,在理论上C肽和胰岛素是等同分泌的,也就是说产生一个胰岛素就会相应产生一个C肽。因为C肽与胰岛素等同分泌,具有相当稳定的比例关系,当我们测出C肽产生的量时,就能了解产生胰岛素的量。且对于已经使用胰岛素治疗的病人,体内产生的胰岛素抗体可能会干扰胰岛素的测定,而注射的外源性胰岛素不含C肽,所以测定血中C肽水平,可以反映体内产生胰岛素的水平。正常状态下C肽水平为0.81-3.85ng/mL。在口服葡萄糖耐量试验的同时可抽血测定空腹血糖负荷后1h、2h C肽水平,对于接受胰岛素治疗的患者,用测定血中胰岛素水平不能评价自身胰岛功能,可以测定C肽水平来评价自身胰岛β细胞功能。通过应用案例1,我们可以发现,在服用本辅助逆转糖尿病的药食用组合物按常规工艺制备而成的丸剂进行调理后,欧阳女士在口服葡萄糖耐量试验中,60min后其C肽的上升量较之前上升了1.23倍,在120min后其C肽的上升量较之前上升了1.5倍,能够看到其胰岛功能正在逐步修复和加强,恢复了自身胰岛素的分泌量,基本达到了停用胰岛素医用药的标准。
尽管参照上面实施例详细说明了本发明,但是通过本公开对于本领域技术人员显而易见的是,在不脱离所述的权利要求限定的本发明的原理及精神范围的情况下,可对本发明做出各种变化或修改。因此,本公开实施例的详细描述仅用来解释,而不是用来限制本发明,而是由权利要求的内容限定保护的范围。
Claims (6)
1.一种辅助逆转糖尿病的药食用组合物,其特征在于,包括有聚葡萄糖、混合谷物粉、海参、乳粉、乳清蛋白、低聚果糖、苦荞提取物、人参、黄精提取物、山药、桑葚、枸杞提取物、茯苓、桑叶提取物、葛根、苦瓜肽、魔芋、沙棘提取物、茶树花提取物、L-阿拉伯糖、蛹虫草、罗汉果、菊粉、三氯蔗糖以及多矿多维。
2.根据权利要求1所述的一种辅助逆转糖尿病的药食用组合物,其特征在于,按质量百分比计,包括有聚葡萄糖15%、混合谷物粉16%、海参1%、乳粉28%、乳清蛋白1%、低聚果糖1%、苦荞提取物6%、人参1%、黄精提取物3%、山药2%、桑葚1%、枸杞提取物2%、茯苓2%、桑叶提取物2%、葛根2%、苦瓜肽4%、魔芋4%、沙棘提取物2%、茶树花提取物2%、L-阿拉伯糖1%、蛹虫草1%、罗汉果1%、菊粉1%、三氯蔗糖0.5%以及多矿多维0.5%。
3.根据权利要求1所述的一种辅助逆转糖尿病的药食用组合物,其特征在于,所述混合谷物粉包括有薏米、玉米低聚肽粉和小米。
4.根据权利要求1所述的一种辅助逆转糖尿病的药食用组合物,其特征在于,所述多矿多维包括有维生素C、维生素A、维生素E、维生素B1、维生素B2、维生素B6、烟酸、叶酸、柠檬酸钙和柠檬酸锌。
5.权利要求1所述的一种辅助逆转糖尿病的药食用组合物作为用于临床治疗II型糖尿病和逆转胰岛素抵抗的药物中的应用。
6.权利要求1所述的一种辅助逆转糖尿病的药食用组合物作为用于临床治疗II型糖尿病和逆转胰岛素抵抗的保健品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010810400.4A CN111728214A (zh) | 2020-08-13 | 2020-08-13 | 一种辅助逆转糖尿病的药食用组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010810400.4A CN111728214A (zh) | 2020-08-13 | 2020-08-13 | 一种辅助逆转糖尿病的药食用组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111728214A true CN111728214A (zh) | 2020-10-02 |
Family
ID=72658411
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010810400.4A Pending CN111728214A (zh) | 2020-08-13 | 2020-08-13 | 一种辅助逆转糖尿病的药食用组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111728214A (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112189845A (zh) * | 2020-10-29 | 2021-01-08 | 天津正大珍吾堂食品股份有限公司 | 一种改善血糖的谷物组合物、其制备方法及应用 |
CN112741873A (zh) * | 2020-12-30 | 2021-05-04 | 三亚海王海洋生物科技有限公司 | 含海参复合多糖粉的组合物、复方制剂及其应用 |
CN113176366A (zh) * | 2021-05-08 | 2021-07-27 | 宁夏医科大学 | 基于谱效关系的二精方多糖及黄酮类成分的评价方法 |
CN113842452A (zh) * | 2021-08-11 | 2021-12-28 | 甘小云 | 治疗糖尿病的药物组合物及其制备方法 |
CN115812959A (zh) * | 2022-12-19 | 2023-03-21 | 河南佳禾康生物食品科技有限公司 | 一种蛋白肽益糖组合物及其制备方法 |
CN117044945A (zh) * | 2023-10-09 | 2023-11-14 | 北京衡美金叶营养健康科技有限公司 | 一种具有控制血糖上升作用的食品组合物及其制备方法和应用 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102406860A (zh) * | 2010-09-25 | 2012-04-11 | 北京信安康生物科技有限公司 | 预防和治疗糖尿病的组合物、其制备方法及应用 |
CN104432108A (zh) * | 2013-09-22 | 2015-03-25 | 天津珍吾堂食品有限公司 | 一种糖尿病人即食谷物粉特膳配方 |
CN105211853A (zh) * | 2015-09-21 | 2016-01-06 | 河南科技大学 | 降糖保健组合物、冲剂及其制备方法 |
CN106262918A (zh) * | 2016-10-14 | 2017-01-04 | 胡松茂 | 一种糖尿病用植物食品配方 |
CN107397213A (zh) * | 2017-08-24 | 2017-11-28 | 长春泉素生物科技有限公司 | 一种糖尿病患者的营养补充餐粉 |
CN108434346A (zh) * | 2018-03-05 | 2018-08-24 | 吴俊� | 一种用于调节、辅助降血糖的药膳组合物及其制备方法 |
CN109221898A (zh) * | 2018-06-04 | 2019-01-18 | 山东龙力生物科技股份有限公司 | 一种含低聚木糖的谷物粉及其制备方法和应用 |
CN110074395A (zh) * | 2019-02-25 | 2019-08-02 | 莫彦明 | 一种降糖补肾的食品配方 |
CN111109602A (zh) * | 2020-01-17 | 2020-05-08 | 杨波 | 一种适合糖尿病及高血脂肥胖人群的药膳功能性食品 |
-
2020
- 2020-08-13 CN CN202010810400.4A patent/CN111728214A/zh active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102406860A (zh) * | 2010-09-25 | 2012-04-11 | 北京信安康生物科技有限公司 | 预防和治疗糖尿病的组合物、其制备方法及应用 |
CN104432108A (zh) * | 2013-09-22 | 2015-03-25 | 天津珍吾堂食品有限公司 | 一种糖尿病人即食谷物粉特膳配方 |
CN105211853A (zh) * | 2015-09-21 | 2016-01-06 | 河南科技大学 | 降糖保健组合物、冲剂及其制备方法 |
CN106262918A (zh) * | 2016-10-14 | 2017-01-04 | 胡松茂 | 一种糖尿病用植物食品配方 |
CN107397213A (zh) * | 2017-08-24 | 2017-11-28 | 长春泉素生物科技有限公司 | 一种糖尿病患者的营养补充餐粉 |
CN108434346A (zh) * | 2018-03-05 | 2018-08-24 | 吴俊� | 一种用于调节、辅助降血糖的药膳组合物及其制备方法 |
CN109221898A (zh) * | 2018-06-04 | 2019-01-18 | 山东龙力生物科技股份有限公司 | 一种含低聚木糖的谷物粉及其制备方法和应用 |
CN110074395A (zh) * | 2019-02-25 | 2019-08-02 | 莫彦明 | 一种降糖补肾的食品配方 |
CN111109602A (zh) * | 2020-01-17 | 2020-05-08 | 杨波 | 一种适合糖尿病及高血脂肥胖人群的药膳功能性食品 |
Non-Patent Citations (2)
Title |
---|
《中国中医药年鉴 学术卷》编辑委员会: "《中国中医药年鉴(学术卷)(2009卷)》", 31 March 2010, 上海中医药大学出版社 * |
路波: "《糖尿病 第2版》", 30 June 2006, 世界图书出版西安公司 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112189845A (zh) * | 2020-10-29 | 2021-01-08 | 天津正大珍吾堂食品股份有限公司 | 一种改善血糖的谷物组合物、其制备方法及应用 |
CN112741873A (zh) * | 2020-12-30 | 2021-05-04 | 三亚海王海洋生物科技有限公司 | 含海参复合多糖粉的组合物、复方制剂及其应用 |
CN113176366A (zh) * | 2021-05-08 | 2021-07-27 | 宁夏医科大学 | 基于谱效关系的二精方多糖及黄酮类成分的评价方法 |
CN113842452A (zh) * | 2021-08-11 | 2021-12-28 | 甘小云 | 治疗糖尿病的药物组合物及其制备方法 |
CN115812959A (zh) * | 2022-12-19 | 2023-03-21 | 河南佳禾康生物食品科技有限公司 | 一种蛋白肽益糖组合物及其制备方法 |
CN117044945A (zh) * | 2023-10-09 | 2023-11-14 | 北京衡美金叶营养健康科技有限公司 | 一种具有控制血糖上升作用的食品组合物及其制备方法和应用 |
CN117044945B (zh) * | 2023-10-09 | 2024-03-15 | 北京衡美金叶营养健康科技有限公司 | 一种具有控制血糖上升作用的食品组合物及其制备方法和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111728214A (zh) | 一种辅助逆转糖尿病的药食用组合物 | |
CN100562259C (zh) | 一种具有稳定餐后血糖的保健面条及其制备方法 | |
CN100579395C (zh) | 一种具有稳定餐后血糖的方便营养粥及其制备方法 | |
CN108112996A (zh) | 一种控制2型糖尿病人群高血糖和提高免疫力的营养组合物 | |
CN104026446A (zh) | 一种适合于高血糖人群服用的营养代餐粉及其制备方法 | |
CN109221898A (zh) | 一种含低聚木糖的谷物粉及其制备方法和应用 | |
CN113521134B (zh) | 一种用于治疗ii型糖尿病的中药组合物与应用 | |
CN100584215C (zh) | 一种具有稳定餐后血糖的保健米及其制备方法 | |
CN102526479A (zh) | 一种增强免疫力、降血糖功能的保健药物配方 | |
CN110839805A (zh) | 一种植物固体饮料 | |
CN113384654A (zh) | 一种降糖组合物及其制备方法和应用 | |
CN112971154A (zh) | 一种富含水溶性膳食纤维及α-淀粉酶抑制剂的固体混合物及其制备方法、应用 | |
CN106110294A (zh) | 一种修复受损胰岛细胞的营养制剂及其制备方法 | |
CN1101133C (zh) | 具有降血糖作用的缮食纤维百乐饼干的配方及其生产工艺 | |
CN110693029A (zh) | 一种降血糖桑叶苦瓜功能食品 | |
CN111214641B (zh) | 一种用于治疗糖尿病的中药制剂 | |
CN102150844A (zh) | 一种具有治疗糖尿病功能的挂面及其制备方法 | |
CN105031248B (zh) | 一种含有硒虫草的可辅助降血糖的保健品 | |
CN114532544A (zh) | 降糖、控糖的谷果植物肽固体饮料 | |
CN106798854A (zh) | 余甘桑叶片及其制备方法 | |
CN110122809A (zh) | 一种糖尿病山药营养强化粉 | |
CN110302213A (zh) | 五谷虫在用于治疗糖尿病中的应用 | |
CN101537102A (zh) | 一种治疗糖尿病的药食两用组合物及其制备方法 | |
CN108114268A (zh) | 一种降低血糖的中药组合物、制剂及其制备方法与应用 | |
CN109430721A (zh) | 一种具有降血糖作用的小麦胚芽组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |